Attenuated early inflammatory response in solid organ recipients with COVID-19

Area of Science:

• Medicine
• Immunology
• Infectious Diseases

Background:

• Immunosuppression increases transplant recipients' risk for severe acute respiratory syndrome 2 (SARS-CoV-2) infection.
• The clinical presentation and management of coronavirus disease 2019 (COVID-19) in immunosuppressed transplant patients remain poorly understood.

Purpose of the Study:

• To investigate the clinical course and features of COVID-19 in solid organ transplant recipients.
• To evaluate the safety and potential benefits of maintaining immunosuppression during SARS-CoV-2 infection in this population.

Main Methods:

• Retrospective analysis of seven solid organ transplant recipients (liver, kidney, lung, heart) with confirmed SARS-CoV-2 infection.
• Extraction of clinical data, including disease course, treatment, and inflammatory markers (e.g., IL-6), from medical records.
• Comparison of inflammatory response with a cohort of non-transplanted intensive care unit (ICU) patients.

Main Results:

• Transplant recipients exhibited an attenuated inflammatory response compared to non-transplanted ICU patients, evidenced by lower Interleukin-6 (IL-6) levels.
• Five patients required immunosuppression adjustments, while all patients continued their immunosuppressive therapy.
• Clinical outcomes varied, with some patients experiencing uncomplicated courses and others requiring mechanical ventilation.

Conclusions:

• Continuous immunosuppression in transplant recipients with SARS-CoV-2 infection appears safe and may be beneficial by preventing hyperinflammation.
• Despite increased susceptibility to SARS-CoV-2, the clinical course in transplanted patients may be comparable to that of immunocompetent individuals.